Tuesday, September 29, 2009

DNA Purity Verification in Microplates Using the A260/A280 Ratio

A common practice in molecular biology is to perform a quick assessment of the purity of nucleic acid samples. While purification of nucleic acid can be accomplished by a number different techniques such as protease digestion followed by organic extraction or by column chromatography, assessment of the purity is almost always carried out by ratiometric spectroscopy at 260 nm and 280 nm. Although this procedure was first described by Warburg and Christian [1] as a means to measure protein purity in the presence of nucleic acid contamination, it is most commonly used today to assess purity of nucleic acid samples. Traditionally this procedure has been performed in spectrophotometers one or two samples at a time using quartz cuvettes. While this method is effective the number of samples that can be determined using this method is limited. The advent of UV/Vis microplate readers and the availability of transparent microplates has allowed for numerous samples to be tested simultaneously.

It is important to note that the A260/A280 ratio is only an indication of purity [2, 3] rather than a precise answer. Pure DNA and RNA preparations have expected A260/A280 ratios of ³1.8 and ³ 2.0 respectively [3] and are based on the extinction coefficients of nucleic acids at 260 nm and 280 nm. Although the A260/A280 ratio is relatively insensitive to change and seemingly useless when DNA/protein mixtures are experimentally tested, the utility of this procedure becomes apparent when nucleic acids are purified from tissue or blood. Tissue samples and to a lesser extent whole cells have a protein content that greatly exceeds that of nucleic acid on a weight basis and purification of samples to a A260/A280 ratio represents an enrichment of nucleic acid that could be as much as 1 million fold.

There are several factors that may affect A260/A280 ratios. The 260 nm measurements are made very near the peak of the absorbance spectrum for nucleic acids, while the 280 nm measurement is located in a portion of the spectrum that has a very steep slope. As a result, very small differences in the wavelength in and around 280 nm will effect greater changes in the A260/A280 ratio than small differences at 260 nm. Consequently, different instruments will result in slightly different A260/A280 ratios on the same solution due to the variability of wavelength accuracy between instruments. Individual instruments, however, should give consistent results. Concentration can also affect the results, as dilute samples will have very little difference between the absorbance at 260 nm and that at 280 nm. With very small differences, the detection limit and resolution of the instrument measurements begin to become much more significant. Pure DNA has an expected A260/A280 ratio of 1.85-2.0. As such the 280 nm value is approximately half that of the 260 nm value. With decreasing nucleic acid concentrations one can imagine that the 280 nm value will eventually be below the detection limit of the microplate reader before the 260 nm value. This is exacerbated in microplates, where the pathlength of the absorbing material is usually less than the 1 cm found with standard cuvettes. Subtraction of background absorbance caused by the microplate of the sample buffer is critical with microplate measurements. Besides the actual measurement the most critical element in the determination of the A260/A280 ratio is the subtraction of the background absorbance of the microplate. This is often referred to as blanking. Blanking requires that one or two wells be filled with buffer only and their respect absorbance values at 260 nm and 280 nm be subtracted from all of the experimental samples. Failure to subtract the background will result in false but believable results at high nucleic acid concentrations and totally aberrant results at low nucleic acid concentrations.

The use of UV/transparent microplate allows for a major increase in throughput for this routine assay. Instead of laboriously reading samples in a cuvette, cleaning the cuvette and loading the next sample, one can read 96 or 384 samples (minus one or two wells for blanking) in minutes instead of hours. Making A260/A280 determinations in microplates will not be any more accurate than cuvettes, but it will save you hours of time.













References

(1) Warburg, O. and W. Christian (1942) Isolation and crystallization of enolase. Biochem. Z. 310:384-421.
(2) Glasel, J.A. (1995) Validity of Nucleic Acid Purities Monitored by A260/A280 Absorbance Ratios, Biotechniques 18:62-63.
(3) Maniatis T., E.F. Fritsch, and J. Sambrook (1982) Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Springs Harbor, NY.






Thursday, September 24, 2009

Cell Dispensing in 1536-well Microplates

Miniaturization of assay volumes is important to reduce amounts of reagents regents used per assay. This is especially true of cell-based assays, where screening campaigns can demand up to 10exp10 cells. 1536-well microplates can reduce the amount of cells required for screening campaigns, sometimes by as much as an order of magnitude. EL406 is a Combination Washer Dispenser that can be used to dispense cells rapidly and with good precision into these high density plates.

Below is an example of the reproducibility of cell dispensing in the preparation of a label-free, cell-based assay:



As can be seen from the graph, using an extracellular matrix (ECM) of fibrinogen, CHO cells could be dispensed across a 1536-well microplate with a precision of 6 %CV, as measured by label-free detection. An application note is available depicting the complete work.


What density microplates do you use for your cell-based assays? If you are not currently using 1536-well densities, will you in the future?

Thursday, September 17, 2009

How Low Can you Go?

Have you ever found yourself wishing you didn’t have to dilute your DNA or RNA samples for a quick quantification? Join the club! There are some novel ways to get around this age-old (ok, not really “age-old”, but pretty old) problem, including instrumentation like NanoView and NanoDrop.

We’ve tried to solve the problem for our customers by making a plate that can be used in our standard microplate readers, especially in the new Epoch. The Take3 plate can be used in the plate reader carrier for up to sixteen 2 µL samples. Fast and simple. Then the next gal (or guy) can go ahead and read their 96 well assay plate, in the same instrument. Couldn’t be easier…but, it could be free…BioTek’s giving away an Epoch and Take3 plate system!

Click here to see how to win!

Wednesday, September 16, 2009

ELRIG / Drug Discovery 2009 Recap

While Mr. Asahi, the robotic "beer"-tender was the hit of the opening reception at ELRIG-SBS last week, there were plenty of other products, posters and presentations of interest at the exhibition.

BioTek presented five posters at the show, primarily focused on collaborative work with Promega automating both cell-based and biochemical assays for hit to lead and lead optimization assays:
  1. Low Volume Nucleic Acid Quantification using A Multi-Volume Microplate Spectrophotometer System
  2. Automation of a Luminescent Assay to measure UDP-glucuronosyltransferase (UGT) Enzyme Activity
  3. Automation of a Multiplexed Cell-based Assay to Measure Simultaneously Inhibition and Induction of the Cytochrome P450 Isoform 3A4 by Small Molecule Compounds
  4. A Simple and Robust Automated Kinase Profiling Platform using Luminescent ADP Accumulation Technology
  5. Automation of Luminescence-based CYP Inhibition Assays using BioTek Instrumentation for use in Drug Discovery


What did you find of most interest at the show? Will you be going to next year’s Drug Discovery 2010 in Coventry?

Tuesday, September 8, 2009

A Cost-Effective Automated Workflow for High-Throughput Screening of G-Protein-Coupled Receptors (GPCRs) Using Fluorescence

Drugs targeting members of the GPCR superfamily represent the core of modern medicine. They account for the majority of the best-selling drugs and roughly 40% of all prescription pharmaceuticals on the market today. The new fluorescent probe for drug discovery FluoForte™, which is provided to cells as a cell membrane-permeable acetoxymethyl (AM) ester, is used to track calcium flux as part of the signal transduction process initiated by GPCR binding. Media is removed and the working dye solution is added using an EL406 Combination Washer Dispenser. Once within the cells, the probe is hydrolyzed by intracellular esterases, leading to the generation of a cell membrane impermeable form, in an analogous manner as commonly used Fluo-3 or Fluo-4 dyes. Intracellular calcium binding to the fluorescent probe increases its fluorescence, which is readily measured using a Synergy Mx reader equipped with a dual-reagent dispenser. This homogeneous fluorescence-based assay workflow is suitable for monitoring calcium mobilization across a broad spectrum of biological targets. The easy-to-use automation protocol does not require the exogenous addition of a quencher dye, which could adversely affect receptor-ligand interaction kinetics. Dye loading in live cells can be performed at 37°C or room temperature, for easier automation. The assay can be performed in a convenient 96-well or 384-well microplate format. The ease-of use of the kit, affordability and high performance of the instruments and minimal installation requirements make the workflow readily accessible, even to academic research groups with modest consumable and instrumentation budgets.

BioTek offers several different instruments that can be used for low cost GPCR screening. The Precision Microplate Sample Processor can be used for drug serial dilution, plate to plate transfer and cell seeding. As mentioned previously, the EL406 can be used to both aspirate media and dispense loading dye. Alternatively, these tasks can be performed using separate instrumentation such as the ELx405 Washer and the MicroFlo Select dispenser. These modular instruments can automate many of the tasks necessary to perform low to medium throughput GPCR screening assays at a reasonable price.















Figure 1. ATP Dose Response in CHO-M1 Cells

Thursday, September 3, 2009

BioTek and the Clinical ELISA Market

Commercial ELISA assay kits represent approximately 15-20% of component microplate instrumentation usage. Of the thousands of combined units sold of the ELx800 and ELx50 over the last 10-14 years 80-90% are used to run clinical or other ELISAs. During this time period BioTek has had collaborations with well over 80 ELISA assay kit providers worldwide that has resulted in the programming of over 1500 assays working successfully on our ELx800, ELx808, ELx50, and ELx405 products.

BioTek’s unique success in the OEM clinical ELISA market specifically has largely been due to our ability to offer individually customized assay performance criteria within a database that is downloaded as an overlay to our onboard software platform. This format offers a fully integrated piece of software on a standalone component instrument that allows easy field upgrades as assays are added or deleted over time. Most custom databases also offer open assay slots so that end users have the flexibility to program in other assays in addition to the customized ones. Some preprogrammed assays also allow some end user flexibility to edit open parameters onboard the instrument to customize the assay even further.

We are looking forward to watching how Gen5CL grows and positions itself in the commercial ELISA market, specifically the clinical ELISA marketplace. Early indications show that the ability to communicate with LIS systems and run customized databases from more than one kit manufacturer through a single product are just two of the value added advantages to this product.